Ian L. Scott, Ph.D.

ACU-3223 Program
Accomplishments Cont'd
dr.i.l.scott@gmail.com
ian_scott_final004006.jpg ian_scott_final004004.gif ian_scott_final004003.gif
[ 1 ]
[ 2 ]
[ 3 ]
[ 4 ]
[ 5 ]
[ 6 ]
[ 7 ]
Dr. Ian L. Scott:
ACU-4429 Research Program Leader:
heartbeat.gif ian_scott_final004001.jpg
More
ACU-3223 was Acucela’s first clinical candidate and completed Phase I trials for the treatment of Age-Related Macular Degeneration. During this time, Dr. Scott created a viable large-scale synthetic route to an oxygen, heat and light sensitive molecule. He managed the CROs responsible for API and drug product manufacture, authored CMC Section 7, and was responsible for the development and implementation of patent protection strategies.
.
Leadership of the working groups with Otsuka in areas of research, CMC, toxicology and non-clinical pharmacology
Creation of overall research plan including staffing and budgets for initial SAR, back-up program, IP, MOA studies, and the creation of new models for ocular disease

Chemistry team leader (5 internal, 6 external chemists); Biology team leader (9 biologists including the vivarium)
Worked with consultants to initiate, manage and complete studies including: 3, 6 and 9-month toxicology, pilot development and pilot fertility
Managed metabolite identification program

Identified major human metabolites
Managed CRO responsible for development and validation of bioanalytical methods for parent and metabolites
Designed and implemented translational toxicology studies

Management of CMC including API, drug product manufacture and CMC Section 7
Determination and implementation of patent protection strategies
Managed chemistry outsourcing to India